The stock of health-care company Regeneron could rise as its antibody treatment sees wider use in the fight against Covid-19, CNBC's Jim Cramer said Monday. Several pharmaceutical and health-care stocks have boomed during the coronavirus pandemic due to their new products used to prevent or treat the disease. However, Cramer said on " Squawk Box " that Regeneron's stock deserved a bigger bounce for the company's monoclonal antibody cocktail. "This is the stock to own if you think this thing is going to continue," Cramer said. On the other hand, he said shares of the vaccine makers, such as Moderna , were "OK" but "inflated." Some studies have shown that Regeneron's treatment reduces the severity of symptoms and chances of death in patients with Covid-19. In July , the Food and Drug Administration expanded its emergency use authorization for Regeneron so that the treatment could be used preventatively before patients developed symptoms. The treatment has become a major part of response efforts in some of the states hit hardest by the delta variant of the virus, including Mississippi and Florida. Shares of Regeneron have gained momentum in recent months, but the stock is up less than 2% over the past year. Moderna, BioNTech , Pfizer and Johnson & Johnson have all outperformed Regeneron during that time frame. Moderna in particular has seen an enormous gain, rising more than 400%.
Scott Mlyn | CNBC
The stock of health-care company Regeneron could rise as its antibody treatment sees wider use in the fight against Covid-19, CNBC's Jim Cramer said Monday.